Table 2 Summary of patient characteristics, clinical indicators, and patient outcomes

Monoclonal antibody therapy

 Bamlanivimab

24 (56)

 Bamlanivimab/etesevimab

10 (23)

 Casirivmab/imdevimab

10 (23)

Age (years)

median (interquartile range)

15 (14–16)

 12 to 13

9 (21)

 14 to 15

17 (39)

 16 to 17

18 (42)

Gender

 Female

25 (57)

 Male

19 (43)

Race

 Caucasian

23 (52)

 Hispanic

11 (25)

 Black

10 (23)

Days of symptoms before MCA

Median (interquartile range)

4 (2-7)

 0 to 3

18 (41)

 4 to 5

11 (25)

 6 to 9

15 (34)

Risk factors (patient may have more ≥ 1 factor)

 Obesity

35 (80)

 Asthma

19 (43)

 Developmental delay

2 (4.5)

 Hypertension

1 (2.3)

 Chest pain

1 (2.3)

 Congenital heart disease

1 (2.3)

 Insulin dependent diabetes mellitus

1 (2.3)

Body mass index

 > 85th percentile

35 (80)

Steroid use

 Last 7 days

6 (14)

Initial oxygen saturation (%)

Median (interquartile range)

98 (98–99)

 Normal, ≥ 95

42 (95)

 Abnormal, < 95

2 (4.5)

Initial heart rate (bpm)

Median (interquartile range)

89 (79–104)

 Normal, < 120

41 (93)

 Abnormal, > 120

3 (6.8)

Initial respiratory rate (breaths per minute)

Median (interquartile range)

20 (18–20)

 Normal, < 24

41 (93)

 Abnormal, ≥ 24

3 (6.8)

Body temperature (celsius)

Median (interquartile range)

36.9° (36.7°–37.4°)

 Normal, < 38 °C

43 (98)

 Abnormal, ≥ 38 °C

1 (2.3)

Clinical outcomes

 Infusion-related event

1 (2.3)

 ED visit within 28 days

2 (4.7)

 Hospitalization within 28 days

0 (0)